RNAC FY 2024 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$39M+49.6% YoY

Gross Profit

$39M100.0% margin

Operating Income

-$44M-112.8% margin

Net Income

-$77M-199.0% margin

EPS (Diluted)

$-3.29

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$33M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$435M

Total Liabilities

$442M

Stockholders' Equity

-$7M

Cash & Equivalents

$213M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$39M	$26M	+49.6%
Gross Profit	$39M	$26M	+49.6%
Operating Income	-$44M	-$86M	+49.2%
Net Income	-$77M	-$220M	+64.8%